University of California

Otonomy, Inc.

Kalypsys, Inc.

Afraxis Holdings, Inc.

Dompe' Farmaceutici S.p.a.

Rqx Pharmaceuticals, Inc.

Sova Pharmaceuticals, Inc.

Sergio G Duron

Benedikt K Vollrath

Luis A Dellamary

Fabrice Piu

Qiang Ye

Jay Lichter

Carl Lebel

Andrew M Trammel

Jeffrey P Harris

Michael Christopher Scaife

James W Malecha

Andrew K Lindstrom

Mehmet Kahraman

Stewart Alwyn Noble

David Alan Campbell

Andrew Shiau

Boliang Lou

Christopher D Bayne

Michael Sertic

Carmen K Robinson

Cunxiang Zhao

Guy Oshiro

Steven P Govek

Warren Stanfield Wade

Srinivas G Rao

Justin Chapman

Simon G Sydserff

Gregory Stein

Robert Higuchi

Peter Andrew Smith

Tucker Curran Roberts

Steve P Govek

Carmen KM Robinson

Steward A Noble

Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.

Auris formulations for treating otic diseases and conditions

Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).

Controlled-release CNS modulating compositions and methods for the treatment of otic disorders

Provided herein are analogs of the natural product arylomycin for the treatment of microbial infections. In some embodiments, the compounds described herein have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broader spectrum of antibiotic bioactivity compared to the natural product. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Broad spectrum antibiotics

Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with aural pressure modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders

Disclosed herein are compositions and methods for the treatment of otic disorders with otic structure modulating compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).

Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders

Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with free-radical modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Controlled release compositions for modulating free-radical induced damage and methods of use thereof

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders.

6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders.

6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders

Disclosed herein are methods for the treatment of otic diseases or conditions with intratympanic compositions and formulations of multiparticulate auris sensory cell modulating agent administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders

Disclosed herein are compositions and methods for the treatment of otic disorders with ion channel modulators. In these methods, the ion channel modulator compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the ion channel modulator compositions and formulations onto the auris interna target areas, or via perfusion into the auris interna structures.

Controlled release ion channel modulator compositions and methods for the treatment of otic disorders

Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

Sulfonyl-substituted bicyclic compounds as modulators of PPAR

Growing community of inventors

San Diego, CA, United States of America

Sergio G Duron